Further nomination secured to Curetis N.V. Supervisory Board
Coulter Partners was delighted to partner once again with German / Dutch diagnostics company Curetis N.V. to secure the nomination of Dr. Prabhavathi Fernandes to the company’s Supervisory Board. Dr. Fernandes is CEO of Cempra Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Curetis has announced that Dr. Fernandes’ proposed election for a three-year term until 2019 will be held at its Annual General Shareholders’ Meeting on June 16, 2016.
“It has been a great pleasure to work with everyone at Coulter Partners again and may I take this opportunity to thank the whole team for conducting another outstanding search on our behalf,” Oliver Schacht, PhD CEO, Curetis N.V.
Dr. Fernandes founded Cempra in January 2006 and has served as President and Chief Executive Officer and a Member of the Board of Directors since then. In 2012, she led the initial public offering and listing on Nasdaq for Cempra, and has successfully raised over half a billion dollars to date for the company, building value for its investors and taking its first antibacterial product candidate from the bench to NDA with the plan to launch the product in the U.S. Her career of more than four decades has focused on anti-infectives, first in clinical microbiology and infectious diseases and then in pharmaceutical discovery and development. Prior to Cempra, Dr. Fernandes held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research, where she was directly involved in the development of antibiotics, four of which have been approved with one achieving sales over a billion dollars. After leaving Bristol-Myers Squibb in 1997, she founded and led three biotechnology and CRO companies and was President and Chief Executive Officer of DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes has served on the U.S. Congressional Panel for Assessment of Impact of Antibiotic Resistant Bacteria and on the American Society for Microbiology Advisory Panel for Antibiotic Resistance, and continues her work on related policy matters. She serves on the editorial board of several journals, was a member of the Product Development working group for Biodefense for the NIAID, and was an Advisory Board Member of Optimer Pharmaceuticals, Inc. as well as the Supervisory Board of GPC Biotech. She has authored over 250 publications and numerous reviews and book chapters. She received her Ph.D. in microbiology from Thomas Jefferson University, Philadelphia.
The full announcement from Curetis follows:
Curetis shall hold its Annual General Shareholders’ Meeting on June 16, 2016 – Nominating Dr. Prabhavathi Fernandes for election to its Supervisory Board
Amsterdam, the Netherlands and Holzgerlingen, Germany, May 2, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the invitation to its annual general shareholders’ meeting (“AGM”).
Curetis will hold its AGM on June 16, 2016, at Steigenberger Hotel, Stationsplein Zuid-West 951, 1117 CE Schiphol-Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 13.30 hours CEST; registration starts at 12.30 hours CEST. Also Curetis will be offering electronic pre-voting starting on May 20, 2016 at 08:00 hours CEST.
A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available at
The most important resolutions in the agenda of the AGM relate to changes in the Supervisory Board, i.e. the proposed election of new Supervisory Board member Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC, USA) for a three-year term until 2019, the resignation of Dr. Frank Mühlenbeck and the re-election of Dr. Holger Reithinger and Dr. Rudy Dekeyser for another one-year term, respectively.
Also on the agenda is the creation of a new Stock Option Program for the Company and associated changes to the Supervisory Board remuneration, making Supervisory Board members also eligible to such new plan, as well as changes to the Management Board’s Remuneration Policy and Stock Option grants.
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment in the commercial register at district court Stuttgart on March 15, 2016 Curetis plc (AG) changed its legal form into Curetis Ltd. (GmbH).
Curetis, Max-Eyth-Str. 42, 71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10 email@example.com or firstname.lastname@example.org
International Media & Investor Inquiries
akampion Dr. Ludger Wess / Ines-Regina Buth, Managing Partners email@example.com Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group, Lee Roth, firstname.lastname@example.org Tel. +1 646 536 7012